Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
You have logged out

Recent articles

 

42-25 SU2C, Merck Taking Proposals For New Uses for Keytruda

(in: The Cancer Letter)
 

42-25 NCI Surgery Branch Resumes Enrollment In Suspended Immunotherapy Trials

(in: The Cancer Letter)
 

42-25 Stanford, Intermountain and Providence Use Syapse Platform to Integrate Their Data

(in: The Cancer Letter)
 

42-25 The Moonshot’s Metric for Success: Avoiding a Single, Tangible Endpoint

(in: The Cancer Letter)
 

42-25 Hirsch: I Dropped Out of Stanford to Start Syapse

(in: The Cancer Letter)
 

(in: The Cancer Letter)
 

42-24 Moonshot May Play Role in $400 Million Annual Contract to Run NCI's Frederick Lab

(in: The Cancer Letter)
 

42-24 Task Force Adds Tests to Colon Screening Guideline

(in: The Cancer Letter)
 

42-24 Guideline Edits Rooted in Science, Former USPSTF Member Says

(in: The Cancer Letter)
 

Letter